Literature DB >> 31211604

Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.

Matthew P Goetz1, Vera J Suman1, Yusuke Nakamura1, Kazuma Kiyotani1, V Craig Jordan1, James N Ingle1.   

Abstract

Entities:  

Year:  2019        PMID： 31211604      PMCID： PMC6675592          DOI： 10.1200/JCO.19.00504

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

2.  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

Authors:  Matthew P Goetz; James M Rae; Vera J Suman; Stephanie L Safgren; Matthew M Ames; Daniel W Visscher; Carol Reynolds; Fergus J Couch; Wilma L Lingle; David A Flockhart; Zeruesenay Desta; Edith A Perez; James N Ingle
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

Review 3.  Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.

Authors:  Kazuma Kiyotani; Taisei Mushiroda; Hitoshi Zembutsu; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2013-05-09       Impact factor: 3.172

4.  Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.

Authors:  Anabel Sanchez-Spitman; Vincent Dezentjé; Jesse Swen; Dirk Jan A R Moes; Stefan Böhringer; Erdogan Batman; Edith van Druten; Carolien Smorenburg; Aart van Bochove; Anneke Zeillemaker; Lynn Jongen; Maartje Los; Patrick Neven; Hans Gelderblom; Henk-Jan Guchelaar
Journal:  J Clin Oncol       Date:  2019-01-24       Impact factor: 44.544

5.  Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.

Authors:  Kazuma Kiyotani; Taisei Mushiroda; Naoya Hosono; Tatsuhiko Tsunoda; Michiaki Kubo; Fuminori Aki; Yutaka Okazaki; Koichi Hirata; Yuichi Takatsuka; Minoru Okazaki; Shozo Ohsumi; Takashi Yamakawa; Mitsunori Sasa; Yusuke Nakamura; Hitoshi Zembutsu
Journal:  Pharmacogenet Genomics       Date:  2010-09       Impact factor: 2.089

6.  Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

Authors:  Marco Colleoni; Shari Gelber; Aron Goldhirsch; Stefan Aebi; Monica Castiglione-Gertsch; Karen N Price; Alan S Coates; Richard D Gelber
Journal:  J Clin Oncol       Date:  2006-02-27       Impact factor: 44.544

7.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors:  Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

8.  CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.

Authors:  Matthew P Goetz; Vera J Suman; Tanya L Hoskin; Michael Gnant; Martin Filipits; Stephanie L Safgren; Mary Kuffel; Raimund Jakesz; Margaretha Rudas; Richard Greil; Otto Dietze; Alois Lang; Felix Offner; Carol A Reynolds; Richard M Weinshilboum; Matthew M Ames; James N Ingle
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

9.  CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Authors:  M A Province; M P Goetz; H Brauch; D A Flockhart; J M Hebert; R Whaley; V J Suman; W Schroth; S Winter; H Zembutsu; T Mushiroda; W G Newman; M-T M Lee; C B Ambrosone; M W Beckmann; J-Y Choi; A-S Dieudonné; P A Fasching; R Ferraldeschi; L Gong; E Haschke-Becher; A Howell; L B Jordan; U Hamann; K Kiyotani; P Krippl; D Lambrechts; A Latif; U Langsenlehner; W Lorizio; P Neven; A T Nguyen; B-W Park; C A Purdie; P Quinlan; W Renner; M Schmidt; M Schwab; J-G Shin; J C Stingl; P Wegman; S Wingren; A H B Wu; E Ziv; G Zirpoli; A M Thompson; V C Jordan; Y Nakamura; R B Altman; M M Ames; R M Weinshilboum; M Eichelbaum; J N Ingle; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2013-09-23       Impact factor: 6.875

10.  Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.

Authors:  P Saladores; T Mürdter; D Eccles; B Chowbay; N K Zgheib; S Winter; B Ganchev; B Eccles; S Gerty; A Tfayli; J S L Lim; Y S Yap; R C H Ng; N S Wong; R Dent; M Z Habbal; E Schaeffeler; M Eichelbaum; W Schroth; M Schwab; H Brauch
Journal:  Pharmacogenomics J       Date:  2014-08-05       Impact factor: 3.550
  10 in total
  8 in total

Review 1.  Moving Pharmacogenetics Into Practice: It's All About the Evidence!

Authors:  Jasmine A Luzum; Natasha Petry; Annette K Taylor; Sara L Van Driest; Henry M Dunnenberger; Larisa H Cavallari
Journal:  Clin Pharmacol Ther       Date:  2021-07-07       Impact factor: 6.903

2.  The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.

Authors:  Jeanine Marie Nardin; Werner Schroth; Thais Abreu Almeida; Thomas Mürdter; Solane Picolotto; Evelyn Castillo Lima Vendramini; Reiner Hoppe; Jenifer Primon Kogin; Diandra Miqueleto; Silvia Dark Robaskievicz de Moraes; Matthias Schwab; Roberto Flavio Pecoits-Filho; Hiltrud Brauch; José Claudio Casali-da-Rocha
Journal:  Clin Transl Sci       Date:  2019-11-09       Impact factor: 4.689

3.  Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast Cancer.

Authors:  Philip S Bernard; Whitney Wooderchak-Donahue; Mei Wei; Steven M Bray; Kevin C Wood; Baiju Parikh; Gwendolyn A McMillin
Journal:  Cancers (Basel)       Date:  2021-03-11       Impact factor: 6.639

4.  Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial.

Authors:  C Louwrens Braal; Anne Kleijburg; Agnes Jager; Stijn L W Koolen; Ron H J Mathijssen; Isaac Corro Ramos; Pim Wetzelaer; Carin A Uyl-de Groot
Journal:  Clin Drug Investig       Date:  2022-01-12       Impact factor: 2.859

5.  Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.

Authors:  C Louwrens Braal; Agnes Jager; Esther Oomen-de Hoop; Justin D Westenberg; Koen M W T Lommen; Peter de Bruijn; Mijntje B Vastbinder; Quirine C van Rossum-Schornagel; Martine F Thijs-Visser; Robbert J van Alphen; Liesbeth E M Struik; Hanneke J M Zuetenhorst; Ron H J Mathijssen; Stijn L W Koolen
Journal:  Clin Pharmacokinet       Date:  2021-11-17       Impact factor: 6.447

6.  Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.

Authors:  Anabel Beatriz Sanchez-Spitman; Dirk-Jan A R Moes; Jesse J Swen; Vincent O Dezentjé; Diether Lambrechts; Patrick Neven; Hans Gelderblom; Henk-Jan Guchelaar
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-29       Impact factor: 3.333

7.  Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen.

Authors:  Lena Klopp-Schulze; Anna Mueller-Schoell; Patrick Neven; Stijn L W Koolen; Ron H J Mathijssen; Markus Joerger; Charlotte Kloft
Journal:  Front Pharmacol       Date:  2020-03-31       Impact factor: 5.810

Review 8.  Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer.

Authors:  Thomas Helland; Sarah Alsomairy; Chenchia Lin; Håvard Søiland; Gunnar Mellgren; Daniel Louis Hertz
Journal:  J Pers Med       Date:  2021-03-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.